Trastuzumab plus pertuzumab for HER2-mutated cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 12 or older.
- Your cancer must have HER2 amplification or a specific HER2 activating mutation on a validated genetic test (tumor gene testing).
- You must be able to provide a fresh tissue biopsy and blood samples for study testing.
- You must not have breast cancer that is only early-stage or has already spread (early or metastatic breast cancer).
- Your heart must be healthy enough for this treatment (based on an ejection fraction and recent heart history).
- You must not be allergic to trastuzumab or pertuzumab and must avoid certain live vaccines around treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (trastuzumab rezetecan) for advanced solid tumors that have a protein called HER2 on their surface. The drug combines an antibody that targets HER2 with a chemotherapy component. It's designed for cancers that have grown despite prior treatment or have no good alternatives.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of three drugs (pyrotinib, trastuzumab, and pertuzumab) as ongoing treatment after initial chemotherapy for HER2-positive advanced breast cancer that has not gotten worse. It aims to see if this maintenance therapy can help keep the cancer under control.
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Hear when a new Gallbladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.